<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193190</url>
  </required_header>
  <id_info>
    <org_study_id>WO39608</org_study_id>
    <secondary_id>2016-004126-42</secondary_id>
    <nct_id>NCT03193190</nct_id>
  </id_info>
  <brief_title>A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)</brief_title>
  <official_title>A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety,
      tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based
      treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma
      (PDAC).

      Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of patients who
      have received no prior systemic therapy for metastatic PDAC, and Cohort 2 will consist of
      patients who have received one line of prior systemic therapy for PDAC. In each cohort,
      eligible patients will be assigned to one of several treatment arms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Anticipated">November 3, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 3, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Objective Response, as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)</measure>
    <time_frame>From randomization until disease progression or loss of clinical benefit (up to approximately 3-5 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs)</measure>
    <time_frame>From first study treatment administration until 30 days after the last dose or until initiation of new systemic anti-cancer therapy, whichever occurs first (up to approximately 3-5 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS), as Determined by Investigator According to RECIST v1.1</measure>
    <time_frame>From randomization up to the first occurrence of disease (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization up to death from any cause (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who are Alive at Month 6</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response, as Determined by Investigator According to RECIST v1.1</measure>
    <time_frame>From the date of first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Disease Control, as Determined by Investigator According to RECIST v1.1</measure>
    <time_frame>From randomization until disease progression or loss of clinical benefit (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Control (Nab-Paclitaxel and Gemcitabine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort 1: Participants will receive Nab-Paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
Participants in the Cohort 1 control arm who experience disease progression will be given the option of enrolling into Cohort 2 (if open for enrollment), provided they meet eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Selicrelumab 16 mg subcutaneous injection on Day 1 of Cycles 1−4 and every third cycle thereafter (i.e. Cycles 7, 10, 13 etc.) of each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Bevacizumab 10 mg/kg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + AB928</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: Participant will receive AB928 150 mg orally once daily on Days 1 to 28 of each 28 day cycle; Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Tiragolumab 420 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Atezolizumab + Cobimetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: Participants will receive Cobimetinib 60 milligrams (mg) once daily orally on Days 1-21 of each 28-day cycle; and Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28-day cycle.
Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arm is open for enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Atezolizumab + PEGPH20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: Participants will receive PEGPH20 3 micrograms per kilogram (mcg/kg) IV infusion on Days 1, 8 and 15 of each 21-day cycle; and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle.
Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Atezolizumab + BL-8040</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: Participants will receive BL-8040 1.25 milligrams per kilogram (mg/kg) subcutaneously (SC) on Days 1-5 of the first week, followed by combination treatment consisting of BL-8040 1.25 mg/kg SC three times a week on non-consecutive days and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle.
Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Atezolizumab + RO6874281 every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: Participants will receive Atezolizumab 840 mg IV infusion on days 1 and 15 of each 28 day cycle; RO6874281 will be administered 10 mg by IV infusion on day 1 and 15 mg on days 8, 15, and 22 for cycle 1 (28 day cycle). RO6874281 will be administered 15 mg by IV infusion on days 1 and 15 of each subsequent 28 day cycle.
Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Atezolizumab + RO6874281 every 3 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: Participants will receive Atezolizumab 1200 mg IV infusion on Day 1 of each 21 day cycle; and RO6874281 10 mg by IV infusion on day 1 of each 21 day cycle.
Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Control (Nab-Paclitaxel and Gemcitabine or mFOLFOX6)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort 2: Participants who progressed on a prior fluoropyrimidine-based regimen will receive Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
Participants who progressed on a prior gemcitabine-based regimen will receive 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6). Participants will receive Oxaliplatin 85 mg/m^2 IV on Days 1 and 15 of each 28 day cycle; Leucovorin 400 mg/m^2 IV on Days 1 and 15 of each 28 day cycle; Fluorouracil 400 mg/m^2 IV push on Days 1 and 15 of each 28 day cycle; and Fluorouracil 2400 mg/m^2 IV continuous infusion over 46 hours on Days 1 and 2 and on Days 15 and 16 of each 28 day cycle.
Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-Paclitaxel</intervention_name>
    <description>Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.</description>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + AB928</arm_group_label>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab</arm_group_label>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab</arm_group_label>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab</arm_group_label>
    <arm_group_label>Cohort 1: Control (Nab-Paclitaxel and Gemcitabine)</arm_group_label>
    <arm_group_label>Cohort 2: Control (Nab-Paclitaxel and Gemcitabine or mFOLFOX6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine will be administered as per the schedule specified in the respective arm.</description>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + AB928</arm_group_label>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab</arm_group_label>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab</arm_group_label>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab</arm_group_label>
    <arm_group_label>Cohort 1: Control (Nab-Paclitaxel and Gemcitabine)</arm_group_label>
    <arm_group_label>Cohort 2: Control (Nab-Paclitaxel and Gemcitabine or mFOLFOX6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin will be administered as per the schedule specified in the respective arm.</description>
    <arm_group_label>Cohort 2: Control (Nab-Paclitaxel and Gemcitabine or mFOLFOX6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Leucovorin will be administered as per the schedule specified in the respective arm.</description>
    <arm_group_label>Cohort 2: Control (Nab-Paclitaxel and Gemcitabine or mFOLFOX6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Fluorouracil will be administered as per the schedule specified in the respective arm.</description>
    <arm_group_label>Cohort 2: Control (Nab-Paclitaxel and Gemcitabine or mFOLFOX6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be administered as per the schedule specified in the respective arm.</description>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + AB928</arm_group_label>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab</arm_group_label>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab</arm_group_label>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab</arm_group_label>
    <arm_group_label>Cohort 2: Atezolizumab + BL-8040</arm_group_label>
    <arm_group_label>Cohort 2: Atezolizumab + Cobimetinib</arm_group_label>
    <arm_group_label>Cohort 2: Atezolizumab + PEGPH20</arm_group_label>
    <arm_group_label>Cohort 2: Atezolizumab + RO6874281 every 2 weeks</arm_group_label>
    <arm_group_label>Cohort 2: Atezolizumab + RO6874281 every 3 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>Cobimetinib will be administered as per the schedule specified in the respective arm.</description>
    <arm_group_label>Cohort 2: Atezolizumab + Cobimetinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEGPH20</intervention_name>
    <description>PEGPH20 will be administered as per the schedule specified in the respective arm.</description>
    <arm_group_label>Cohort 2: Atezolizumab + PEGPH20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BL-8040</intervention_name>
    <description>BL-8040 will be administered as per the schedule specified in the respective arm.</description>
    <arm_group_label>Cohort 2: Atezolizumab + BL-8040</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selicrelumab</intervention_name>
    <description>Selicrelumab will be administered as per the schedule specified in the respective arm.</description>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab will be administered as per the schedule specified in the respective arm.</description>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO6874281</intervention_name>
    <description>RO6874281 will be administered as per the schedule specified in the respective arm</description>
    <arm_group_label>Cohort 2: Atezolizumab + RO6874281 every 2 weeks</arm_group_label>
    <arm_group_label>Cohort 2: Atezolizumab + RO6874281 every 3 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB928</intervention_name>
    <description>AB928 will be administered as per the schedule specified in the respective arm.</description>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + AB928</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiragolumab</intervention_name>
    <description>Tiragolumab will be administered as per the schedule specified in the respective arm.</description>
    <arm_group_label>Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma

          -  For patients in Cohort 1: no prior systemic treatment for PDAC

          -  For patients in Cohort 2: disease progression during administration of either 5-FU− or
             gemcitabine-based first-line chemotherapy

          -  Life expectancy greater than or equal to 3 months

          -  Availability of a representative tumor specimen that is suitable for determination of
             programmed death-ligand 1 (PD-L1) and/or additional biomarker status via central
             testing

          -  Measurable disease (at least one target lesion) according to RECIST v1.1

          -  Adequate hematologic and end-organ function test results

          -  Tumor accessible for biopsy

          -  For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use contraceptive measures, and agreement to refrain from
             donating eggs, as outlined for each specific treatment arm

          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive measures, and agreement to refrain from donating sperm, as outlined for
             each specific treatment arm

        Exclusion Criteria:

          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage
             procedure (i.e., more than one time per month)

          -  Symptomatic, untreated, or actively progressing central nervous system (CNS)
             metastases

          -  History of leptomeningeal disease

          -  Active or history of autoimmune disease or immune deficiency

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest computed tomography (CT) scan

          -  Positive human immunodeficiency (HIV) test at screening or at any time prior to
             screening

          -  Active hepatitis B or C virus infection or active tuberculosis

          -  Severe infection within 4 weeks prior to initiation of study treatment

          -  Prior allogeneic stem cell or solid organ transplantation

          -  History of malignancy other than pancreatic carcinoma within 2 years prior to
             screening, with the exception of those with a negligible risk of metastasis or death
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: WO39608 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helen Diller Fam Comp Can Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lombardi Cancer Center, Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uni of Chicago Medical Center; Room M454</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hillman Cancer Center;Medical Oncology</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31620</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. G. U Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

